NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer

The NANT Cancer Vaccine, The First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation.   Personalized Molecular Informed Therapy with NantHealth’s GPS Cancer as The Complementary...

NantKwest to Present at Upcoming Investor Conferences

CULVER CITY, CALIFORNIA-(BUSINESS WIRE), MARCH 3, 2016 NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference...